Processa Pharmaceuticals

47 articles about Processa Pharmaceuticals

• Processa Pharmaceuticals, Inc. Mourns the Sudden Passing of Board Member Virgil Thompson

  11/13/2023

  Processa Pharmaceuticals, Inc. announced with great sadness that Virgil Thompson, Director, passed away unexpectedly on November 9, 2023.

• Processa Pharmaceuticals to Present at the 20th Orphan Drugs and Rare Diseases Global Congress 2023 Americas

  11/9/2023

  Processa Pharmaceuticals, Inc. announces that Dr. David Young, President of Research and Development, will present at the 20th Orphan Drugs and Rare Diseases Global Congress 2023 Americas.

• Processa Pharmaceuticals Announces Formation of Oncology Advisory Board with Renowned Key Opinion Leaders

  11/1/2023

  Processa Pharmaceuticals, Inc. announces the formation of its Oncology Advisory Board featuring key opinion leaders from multiple nationally-recognized institutions.

• Processa Pharmaceuticals to Present at the ThinkEquity Conference

  10/13/2023

  Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, announces that CEO George Ng will present an updated corporate overview at the ThinkEquity Conference.

• Processa Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

  9/6/2023

  Processa Pharmaceuticals, Inc. announces that Chief Executive Officer George Ng will present a corporate overview at the at the H.C. Wainwright 25th Annual Global Investment Conference.

• Processa Pharmaceuticals Provides Data Update Supporting a Potential Personalized Treatment Approach for Improved Cancer Care

  8/17/2023

  Processa Pharmaceuticals, Inc. provides an interim analysis from its ongoing Phase 1B trial of Next Generation Capecitabine (NGC-Cap) in patients with gastrointestinal cancer, which identifies a personalized treatment approach that may yield improved safety and treatment efficacy.

• Processa Pharmaceuticals to Present at the Sidoti & Co. Micro Cap Virtual Conference

  8/10/2023

  Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company now focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, announces that David Young, President of Research and Development, will present a corporate overview at the Sidoti & Co. Micro Cap Virtual Conference being held on August 16 – 17, 2023.

• Processa Pharmaceuticals Appoints Life Sciences Industry Veteran George Ng as Chief Executive Officer

  8/8/2023

  Processa Pharmaceuticals, Inc. announces today that industry veteran George Ng has been appointed to serve as the Company’s Chief Executive Officer and as a Board Director as of August 8, 2023.

• Processa Pharmaceuticals to Participate in a Panel on Interaction with the FDA at the World Orphan Drug Congress

  5/22/2023

  Processa Pharmaceuticals, Inc. today announces CEO David Young, Pharm.D., Ph.D. will participate in a panel at the World Orphan Drug Congress to be held at the Gaylord National Resort & Convention Center in Washington, D.C. May 23-25, 2023.

• Processa Pharmaceuticals Provides Corporate Update and Announces Year End 2022 Financial Results

  3/30/2023

  Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a developer of Next Generation Chemotherapy drugs that provide a better safety-efficacy profile than their widely used FDA-approved counterparts, today provided an update on their clinical programs and announced financial results for the year ended December 31, 2022.

• Processa Pharmaceuticals to Host Conference Call to Discuss 2022 Year End Results and Provide Drug Development Update on March 30, 2023 at 4:30 p.m. EST

  3/23/2023

  Processa Pharmaceuticals, Inc. today announced that it will host a conference call and live webcast on March 30, 2023 at 4:30 p.m. EST to discuss its 2022 results and provide an update on its clinical pipeline for 2023.

• Processa Pharmaceuticals Announces First Patient Dosed in the 300 mg Dose Group with Next Generation Chemotherapy-Capecitabine

  3/17/2023

  Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a developer of Next Generation Chemotherapies (NGCs), today announced that the Company has dosed the first patient in its NGC-Capecitabine (combination of PCS6422 and capecitabine) 300 mg dose group.

• Processa Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference

  3/7/2023

  Processa Pharmaceuticals, Inc. today announced that the Company’s President & CEO, Dr. David Young, will present virtually at the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023 at 12:00 PM Eastern.

• Processa Pharmaceuticals Announces Prioritization on Development of Next Generation Chemotherapies

  2/21/2023

  Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”) reiterates the strategic prioritization of its pipeline of proprietary oncology drugs, defined as Next Generation Chemotherapies (NGCs).

• Processa Pharmaceuticals To Present an Update on Its Future Therapeutic Focus and Strategy at the Biotech Showcase on January 11, 2023.

  1/4/2023

  Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), Dr. David Young, Processa Pharmaceuticals, CEO will present an update on Processa’s future therapeutic focus and strategy at the upcoming Biotech Showcase on January 11, 2023, at 10 am.

• Processa Pharmaceuticals Announces PCS12852 Successfully Improves the Clinical Symptoms Associated with Gastroparesis in Phase 2A Trial

  12/14/2022

  Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a diversified clinical-stage company developing products to improve survival and/or the quality of life for patients who have an unmet medical need condition, today announced positive top-line results on the clinical symptoms associated with gastroparesis from a 4-week Phase 2A study of PCS12852, which is being developed for the treatment of patients with gastroparesis.

• Processa Pharmaceuticals Announces Third Quarter Financial Results and Provides Corporate Update

  11/8/2022

  Processa Pharmaceuticals, Inc. announced financial results for the quarter ended September 30, 2022, and provided an update on its clinical programs.

• PCS12852 Improves Gastric Emptying in Gastroparesis Patients

  11/8/2022

  Processa Pharmaceuticals, Inc. announces positive gastric emptying results from its PCS12852 Phase 2A trial in patients with moderate to severe gastroparesis.

• Processa Pharmaceuticals to Host Conference Call to Discuss Third Quarter 2022 Results and Provide Drug Development Update on November 8, 2022 at 4:30 p.m. EST

  11/2/2022

  Processa Pharmaceuticals, Inc. announces today it will host a conference call and live webcast on November 8, 2022, at 4:30 p.m. EST to discuss its third quarter 2022 results and provide an update on its clinical pipeline.

• Processa Successfully Identifies Next Generation Capecitabine Dosage Regimens for Phase 2B Trial

  11/1/2022

  Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a diversified clinical-stage company developing products to improve survival and/or the quality of life for patients who have an unmet medical need condition, announces positive results from its ongoing Next Generation Capecitabine (NGC) Phase 1B trial.